IGF-1 DES (DES(1-3) IGF-1) is a truncated peptide approximately 10-fold more potent than standard IGF-1 due to its negligible binding affinity to IGF-binding proteins (IGFBPs). This characteristic allows it to remain in its free, biologically active form at the injection site far longer than full-length IGF-1, enabling potent and localized anabolic signaling with reduced systemic distribution.
Because IGF-1 DES is an unregulated research chemical not approved for human use by the FDA or EMA, this guide is strictly educational. Any use outside of controlled research settings carries unknown risks. This content should not be interpreted as medical advice, and users should consult qualified healthcare professionals before considering any application.
The established dosing range for IGF-1 DES is 20–100 mcg administered via intramuscular injection, once to twice daily.
Key baseline parameters:
- Minimum effective dose: 20 mcg per injection
- Standard research dose: 50 mcg per injection
- Maximum recommended dose: 100 mcg per injection
- Frequency: Once daily (conservative approach) to twice daily (advanced protocol)
- Route: Intramuscular injection only
- Cost: $40–$120 per month depending on dosage and supply source
Most users initiating IGF-1 DES dosing begin at the lower end of the range (20–40 mcg per injection) to assess tolerance and localized response before advancing dosing.
Because IGF-1 DES has not been proven effective for fat loss, injury recovery, joint health, anti-inflammation, cognition, mood, stress, longevity, immune support, skin/hair, liver health, or hormonal balance in humans, dosing recommendations are extrapolated from mechanistic research and empirical user reports rather than validated clinical protocols.
For localized muscle hypertrophy and protein synthesis activation:
- Conservative protocol: 20–40 mcg once daily, intramuscular injection into the target muscle
- Standard protocol: 50–75 mcg once daily, intramuscular injection into the target muscle
- Advanced protocol: 50–100 mcg twice daily (morning and evening), intramuscular injection into the target muscle
The twice-daily advanced approach aims to maintain elevated local signaling through the PI3K/Akt/mTOR and MAPK/ERK pathways at the injection site, theoretically maximizing myoblast proliferation and satellite cell activation within that specific muscle.
For systemic anabolic signaling (if attempting whole-body effects):
- Dose: 50–100 mcg once daily
- Frequency: Single daily injection
- Rationale: While IGF-1 DES exhibits reduced systemic distribution compared to full-length IGF-1, higher single doses or once-daily injection may produce mild whole-body anabolic effects, though localized hypoglycemia risk increases.
Injection site selection:
IGF-1 DES is administered exclusively via intramuscular injection. Site-specific injection into the target muscle allows localized anabolic signaling with minimal systemic exposure. Common injection sites include:
- Deltoids (shoulders)
- Quadriceps (front of thigh)
- Pectorals (chest)
- Lats (back)
- Triceps (back of arm)
Injection technique:
- Preparation: Draw the prescribed volume into a sterile insulin syringe or peptide injection syringe (typically 0.5–1 mL capacity). Ensure the solution is at room temperature or slightly cool.
- Site cleaning: Cleanse the injection site with an alcohol pad (70% isopropyl alcohol) and allow to air dry for 15–30 seconds.
- needle insertion: Insert the needle perpendicular to the skin into the muscle at a 90-degree angle. A 27–30 gauge needle is standard for peptide injection.
- Injection: Slowly depress the plunger to deliver the full dose over 3–5 seconds.
- Needle removal: Withdraw the needle at the same angle of insertion.
- Post-injection care: Apply light pressure with a clean cotton pad if bleeding occurs. Do not massage the injection site, as this may promote systemic distribution and reduce localized effect.
Syringe and needle specifications:
- Insulin syringes (0.5–1 mL) with 27–30 gauge needles are standard for peptide administration
- Do not use larger-gauge needles, as they increase injection site trauma
- Maintain sterile technique throughout preparation and administration
- Use a new, sterile needle for each injection
Cycle length for IGF-1 DES:
Because IGF-1 DES is a research compound without established human safety data, cycle recommendations are speculative:
- Short cycle: 4–6 weeks on, 2–4 weeks off
- Standard cycle: 8–12 weeks on, 4–6 weeks off
- Extended cycle: 12–16 weeks on, 6–8 weeks off
The rationale for cycling is to minimize tolerance development, reduce accumulation of local inflammation, and assess recovery of endogenous growth signaling during off-periods. No clinical evidence supports any specific cycle duration.
Timing within the day:
- Once-daily dosing: Administer in the morning, post-workout, or pre-bedtime, depending on personal preference and lifestyle. Post-workout timing (within 2 hours of resistance training) may theoretically enhance localized myoblast proliferation when combined with mechanical stimulus.
- Twice-daily dosing: Space injections 8–12 hours apart (e.g., 8 AM and 8 PM) to maintain more consistent local IGF-1R signaling at the injection site.
Timing relative to meals:
IGF-1 DES can trigger localized hypoglycemia, particularly near vascular tissue. Consuming a carbohydrate source 15–30 minutes after injection may mitigate hypoglycemic symptoms (light-headedness, tremor). Alternatively, inject after meals when blood glucose is elevated.
Beginner protocol (first-time users):
- Starting dose: 20–30 mcg per injection
- Frequency: Once daily
- Injection site: Single large muscle (e.g., quadriceps or deltoid)
- Cycle: 6 weeks on, 3 weeks off
- Rationale: Minimal systemic exposure, rapid assessment of local tolerability, and straightforward monitoring of injection site response
Beginners should observe injection site redness, swelling, pain, and any signs of local hypoglycemia (cold sweating, tremor near injection site) before advancing dosage.
Advanced protocol (experienced users):
- Dose: 50–100 mcg per injection
- Frequency: Twice daily or strategic once-daily dosing in multiple muscles per week
- Injection sites: Rotation among 4–6 different muscles (e.g., Monday deltoid, Tuesday quadriceps, Wednesday pectoral, etc.)
- Cycle: 12–16 weeks on, 6–8 weeks off
- Rationale: Maximized localized signaling across multiple muscle groups, distributed injection site stress, and sustained anabolic stimulus
Advanced users may also integrate IGF-1 DES dosing with periodized resistance training (e.g., higher doses during hypertrophy-focused phases, lower doses during strength or endurance blocks).
1. Exceeding 100 mcg per injection
Doses above 100 mcg per injection lack research support and increase systemic hypoglycemia risk without proportional benefit. Hypoglycemia can manifest as sudden weakness, visual disturbances, seizure (in severe cases), and potential injury during resistance training.
2. Intravenous or subcutaneous injection
IGF-1 DES must be administered intramuscularly. Subcutaneous or intravenous routes dramatically increase systemic exposure, hypoglycemia risk, and unwanted systemic effects (headache, lightheadedness, potential mitogenic activity).
3. Injecting without adequate meal timing
Administering IGF-1 DES without ensuring adequate blood glucose (via recent meals or carbohydrate intake 15–30 minutes post-injection) increases localized hypoglycemia risk and associated symptoms.
4. Repeated injection into the same site
Rotating injection sites among different muscles minimizes localized inflammation, injection site pain, redness, and swelling. Injecting the same muscle daily without rotation causes chronic irritation and tissue damage.
5. Cycling too infrequently
Continuous dosing without off-cycles may promote tolerance, sustained local inflammation, and unknown long-term effects. Standard practice suggests 4–6 week off-periods following 8–12 week on-cycles.
6. Inadequate sterile technique
Non-sterile injection equipment or technique risks bacterial contamination, localized infection, abscess formation, and systemic infection. Always use sterile, single-use needles and syringes, and maintain aseptic technique throughout preparation and administration.
7. Dosing without baseline health assessment
IGF-1 DES activates IGF-1 receptors, which are expressed on multiple cell types including pre-existing tumor cells. Users with undetected malignancies, family history of cancer, or elevated cancer risk should avoid IGF-1 DES. Pre-use medical screening is essential.
| Parameter | Conservative | Standard | Advanced |
|---|
| Dose per injection | 20–30 mcg | 50–75 mcg | 50–100 mcg |
| Frequency | Once daily | Once to twice daily | Twice daily or rotating sites |
| Route | Intramuscular | Intramuscular | Intramuscular |
| Cycle on (weeks) | 6 | 8–12 | 12–16 |
| Cycle off (weeks) | 3 | 4–6 | 6–8 |
| Cost per month | $40–$60 | $60–$90 | $90–$120 |
| Injection sites | 1 muscle | 1–2 muscles | 4–6 muscles (rotating) |
| Best timing | Post-workout or evening | Post-workout or morning | Post-workout or 8 AM / 8 PM split |
| Experience level | First-time users | Intermediate users | Experienced research users |
IGF-1 DES dosing ranges from 20–100 mcg per intramuscular injection, once to twice daily, depending on experience level and goals. Beginner users should start at 20–30 mcg once daily into a single muscle, while advanced users may employ 50–100 mcg twice daily with site rotation. Cycling 8–12 weeks on and 4–6 weeks off is standard practice to minimize tolerance and systemic effects.
Monthly cost ranges from $40–$120 depending on dosage. Proper intramuscular injection technique, site rotation, adequate carbohydrate intake post-injection, and pre-use health screening are critical for safety and efficacy.
Because IGF-1 DES is an unregulated research chemical with no human clinical efficacy data for muscle growth, injury recovery, or any other outcome, all dosing recommendations remain speculative and extrapolated from mechanistic research. This guide is educational only and does not constitute medical advice. Consult qualified healthcare professionals before any use.